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Abstract: 18F-Sodium Fluoride (NaF) accumulates in areas of active hydroxyapatite deposition and
potentially unstable atherosclerotic plaques. We assessed the presence of atherosclerotic plaques in
50 adult patients with HIV (HIV+) who had undergone two cardiac computed tomography scans
to measure coronary artery calcium (CAC) progression. CAC and its progression are predictive
of an unfavorable prognosis. Tracer uptake was quantified in six arterial territories: aortic arch,
innominate carotid artery, right and left internal carotid arteries, left coronary (anterior descending
and circumflex) and right coronary artery. Thirty-one patients showed CAC progression and 19 did
not. At least one territory with high NaF uptake was observed in 150 (50%) of 300 arterial territories.
High NaF uptake was detected more often in non-calcified than calcified areas (68% vs. 32%), and in
patients without than in those with prior CAC progression (68% vs. 32%). There was no correlation
between clinical and demographic variables and NaF uptake. In clinically stable HIV+ patients, half
of the arterial territories showed a high NaF uptake, often in the absence of macroscopic calcification.
NaF uptake at one time point did not correlate with prior progression of CAC. Prospective studies
will demonstrate the prognostic significance of high NaF uptake in HIV+ patients.
Keywords: immune deficiency syndrome; sodium fluoride; atherosclerosis; calcification
1. Introduction
The survival of HIV infected (HIV+) patients has increased significantly over the past several
decades although it is still far from that of the general population [1]. However, the improved
survival has been paralleled by a rise in the incidence of premature cardiovascular events, and
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cardiovascular disease is now among the leading causes of morbidity and mortality in HIV+
patients [2,3]. Atherosclerosis is the result of multiple contributing causes that include a higher
prevalence of traditional risk factors, the HIV virus and other viral associated infections, as well
as antiretroviral medications and their attendant metabolic alterations [4]. Molecular imaging offers
an opportunity to image atherosclerosis in its early stages using probes that visualize activity within
the plaque, taking advantage of specific mechanisms inherent in plaque formation. Positron emission
tomography (PET) imaging with 18F-sodium fluoride (NaF) has been used for several decades to
detect bone malignancies since this radiotracer adheres with high affinity on the surface of growing
crystals of hydroxyapatite [5]. Active calcification is an integral part of atherosclerosis and initial
publications reported visualization of atherosclerotic lesions in the carotid arteries and aorta of patients
undergoing PET-computed tomography (PET-CT) imaging for oncological diagnostic purposes [6].
Subsequent publications highlighted the association of NaF with risk factors for atherosclerosis, risk
scoring algorithms such as the Framingham risk score and even plaques with morphological features
of instability on CT angiography and intraluminal coronary imaging [7–10]. In a seminal publication,
Joshi et al. [11] showed that NaF accumulated preferentially in the culprit plaques of patients with
a recent cerebrovascular event or acute coronary syndromes. Two groups of investigators reported
that high NaF activity in the aortic and mitral valve leaflets at baseline predicted the development
of valvular calcification and dysfunction during follow-up [12,13]. Hence, NaF may be an excellent
marker of atherosclerotic disease activity and an indicator of the propensity to develop cardiovascular
calcification, a predictor of high-risk of events in the general population. Therefore, we hypothesized
that NaF imaging will detect ongoing and more prominent arterial osteogenesis in patients with
significant progression of coronary artery calcium (CAC) in prior sequential CT scans of the chest.
Hence, our objective was to assess the relationship between prior CAC progression and current NaF
activity in several arterial beds.
2. Results
Fifty adult HIV+ patients (84% men, mean age 57 ± 8 years) were enrolled. According to the
predefined study methodology, 31 patients were classified as having had CAC progression and 19
as not having had CAC progression prior to NaF imaging. Table 1 summarizes the patients’ clinical
characteristics based on CAC progression or non-progression. Few characteristics differentiated
patients with CAC progression from those without: there were more men among patients with
progression, patients were older, had a higher baseline CAC score, had a more frequent history of
hypertension and the total and LDL cholesterol as well as the CD4 nadir count were significantly
lower. Half of the patients had at least one area of high NaF uptake (Figure 1) in each of the six arterial
territories: 20 had a high uptake in the right and 24 in the left carotid artery; 20 had a high uptake in
the innominate artery; 25 had a high NaF uptake in the aortic arch. Finally, 24 patients had a high
uptake in the right and 37 in the left coronary artery. In total, 150 of 300 (50%) arterial territories
showed at least one area of high NaF uptake. Figure 2 shows the distribution -expressed as percentage
of patients- of high NaF uptake in 0 to 6 arterial territories. Only one patient had no high NaF uptake
in any territory, while most patients showed involvement of 1–4 territories.
Int. J. Mol. Sci. 2019, 20, 1183 3 of 13
Table 1. Patients’ clinical characteristics.
Variables Total No Progression Progression p-Value
50 19(38%) 31(62%)
Demographic and anthropometric variables
Age, mean (±SD) 57.1 (7.82) 52.53 (4.64) 59.9 (8.1) <0.001
Men (%) 42 (84%) 13 (68.42%) 29 (93.55%) 0.05
Pack year smoking, median (IQR) 15 (0–33.75) 16.88 (6.5–30.2) 13.2 (0–34.5) 0.88
BMI, kg/m2, mean (±SD) 26.01 (4.14) 25.66 (4.2) 26.21 (4.16) 0.67
Waist circumference, cm, mean (±SD) 96.78 (11.3) 96.81 (11.65) 96.76 (11.31) 0.99
HIV variables
Nadir CD4 c/microL, median (IQR) 200 (107.5–324) 249.5 (142.75–430.5) 170 (59–286) 0.02
HIV duration, months, median (IQR) 277.5 (191.25–354) 267 (113–340) 287 (239.5–358.5) 0.19
CD4/CD8 ratio, mean (±SD) 0.97 (0.41) 1.01 (0.37) 0.94 (0.44) 0.60
Undetectable HIV viral load (%) 50 (100%) 19 (100%) 31 (100%) 1.0
Cumulative exposure to INSTIs, months, median (IQR) 36 (14–73.5) 28.5 (5.5–47.25) [12] 39 (23–98) 0.12
Cumulative exposure to NNRTIs, months, median (IQR) 63.5 (29.25–123.75) 39.5 (24–77.5) [10] 79.5 (29.75–126.5) 0.23
Cumulative exposure to NRTIs, months, median (IQR) 169 (103.5–235) 128 (55–196) 187.5 (136–251.75) 0.03
Cumulative exposure to PIs, months, median (IQR) 123 (51–172) 94.5 (50.75–136.5) 129 (51–188) 0.19
Laboratory variables
CRP, mean (±SD) 0.24 (0.29) 0.22 (0.15) 0.25 (0.35) 0.57
Triglycerides, mg/dL, mean (±SD) 160.2 (160.51) 206.53 (231.96) 133.03 (92.68) 0.16
LDL cholesterol, mg/dL, mean (±SD) 103.26 (33.04) 124.71 (31.33) 90.69 (27.39) <0.001
HDL cholesterol, mg/dL, mean (±SD) 46.13 (12.07) 45.59 (11.25) 46.45 (12.72) 0.82
Total cholesterol, mg/dL, mean (±SD) 173.15 (39.83) 198.88 (29.03) 158.07 (37.83) <0.001
Glucose, mg/dL, mean (±SD) 103.26 (31.15) 95.06 (16.17) 108.34 (36.94) 0.30
HOMA, mean (±SD) 3.52 (4.24) 3.62 (3.06) 3.46 (4.97) 0.22
CKD-Epi, mL/min/1.73 m2, mean (±SD) 79.77 (22.49) 85.73 (21.72) 76.33 (22.78) 0.28
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Table 1. Cont.
Variables Total No Progression Progression p-Value
50 19(38%) 31(62%)
Comorbidities
CKD (%) 19 (38%) 5 (26.32%) 14 (45.16%) 0.30
COPD (%) 4 (8%) 0 (0%) 4 (12.9%) 0.27
Osteoporosis (%) 15 (30%) 4 (21.05%) 11 (35.48%) 0.44
Dyslipidemia (%) 49 (98%) 19 (100%) 30 (96.77%) 1
Cardiovascular variables
Statin use (%) 7 (14%) 2 (10.53%) 5 (16.13%) 0.89
Systolic blood pressure, mmHg, mean (±SD) 127.25 (15.29) 121.94 (11.34) 130.43 (16.59) 0.08
Diastolic blood pressure, mmHg, mean (±SD) 81.58 (8.82) 81.33 (8.51) 81.73 (9.15) 0.88
ASCVD, mean (±SD) 10.31 (9.9) 7.39 (7.05) 13.59 (11.99) 0.21
Calcium score, median (IQR), 104 (38.5–348) 4 (2–6) 206 (104–490) 0.05
Hypertension (%) 33 (66%) 8 (42.11%) 25 (80.65%) 0.01
Type 2 diabetes mellitus (%) 14 (28%) 5 (26.32%) 9 (29.03%) 1
CVD (%) 7 (14%) 1 (5.26%) 6 (19.35%) 0.33
Nuclear medicine variables
Aortic arch TBR 1.65 (0.52) 1.53 (0.51) 1.73 (0.52) 0.16
Innominate artery TBR 1.66 (0.49) 1.67 (0.57) 1.65 (0.45) 0.87
Right carotid artery TBR 1.69 (0.8) 1.59 (0.72) 1.75 (0.85) 0.42
Left carotid artery TBR 1.64 (0.66) 1.51 (0.69) 1.72 (0.63) 0.14
RCA TBR 1.65 (0.41) 1.6 (0.39) 1.67 (0.43) 0.55
LCA TBR 2.08 (0.66) 1.93 (0.43) 2.17 (0.76) 0.42
Legend: ASCVD: atherosclerotic cardiovascular disease risk score: BMI: body mass index. CKD: chronic kidney disease. COPD: chronic obstructive pulmonary disease. CRP: C-reactive
protein. CVD: cardiovascular disease. HDL: high density lipoprotein. HOMA: homeostatic model assessment INSTI: integrase strand transfer inhibitors. LCA: left coronary artery. LDL:
low density lipoprotein. NNRTI: non-nucleoside reverse transcriptase inhibitors. NRTI: nucleoside reverse transcriptase inhibitors. PI: protease inhibitors. RCA: right coronary artery. TBR:
target to background ratio.
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Figure 1. Example of carotid artery 18F-Sodium Fluoride uptake in a 50 years old patient with HIV. 
The image on the left is a coronal reconstrution of the PET image of the neck and base of the skull of 
this patient. The white arrow points at one of several areas of enhanced 18F-Sodium Fluoride uptake 
along the course of the right internal carotid artery. The image on the top right is an axial computed 
tomography section of the neck of the same patient, and the white arrow points at a calcified lesion 
corresponding to the lesion seen on the PET image on the left. The bottom right image is a fusion of 
axial PET and CT images; the white arrow points again at the same lesion shown in the axial CT image 
above, demonstrating 18F-Sodium Fluoride uptake in correspondence with the calcification. 
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The average TBR in patients with and without prior CAC progression was similar in all arterial
territories (Table 1). Figure 3 shows the distribution of NaF uptake assessed as TBR in each arterial
territory. NaF uptake was detected 93 times (62%) in areas without CAC and 57 times (38%) in areas
with CAC. A high NaF arterial uptake was observed more frequently in patients who had had no CAC
progression between scans (68%), than in patients with prior CAC progression (32%). The Spearman
correlation coefficient between no prior progression of CAC and high NaF uptake was -0.56 (p = 0.01).
Conversely, the Spearman correlation coefficient between prior CAC progression and NaF uptake was
0.20 (p = 0.33). There was no correlation between any clinical, laboratory and demographic variable
and NaF uptake. Multivariable analyses did not identify any variable associated with a high NaF
uptake in any of the arterial sites.
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Figure 2. Proportion of patients showing high 18F-Sodium Fluoride uptake in 6 arterial territories. 
Only one patient had no uptake while 80% of the patients showed enhanced uptake in 1–4 territories. 
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Figure 2. Proportion of patients showing high 18F-Sodium Fluoride uptake in 6 arterial territories.
Only one patient had no uptake while 80% of the patients showed enhanced uptake in 1–4 territories.
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Figure 3. Proportional distribution of 18F-Sodium Fluoride uptake assessed as target-to-background 
ratio in each arterial territory. The vertical line identifies a target-to-background ratio of 1.6 that was 
chosen as a threshold for high 18F-Sodium Fluoride uptake. 
3. Discussion 
Our findings are novel, as NaF imaging has never been attempted before in HIV+ patients. 
Calcification is a process inherent in atherosclerotic plaque formation and it proceeds through active 
mechanisms resembling bone formation; as NaF accumulates in areas of microcalcification, it is 
considered an optimal tracer to detect plaque growth. We described a NaF uptake prevalence of 50% 
in six arterial territories of ambulatory, stable patients infected with HIV. There was no correlation 
between prior CAC progression and active vascular osteogenesis at a later time point. Several areas 
of NaF uptake at the time of PET imaging did not correspond with macroscopic areas of calcification 
on CT, and NaF uptake was not associated with any clinical or demographic characteristic of the 
patients enrolled.  
Our main intention in designing this study was to investigate whether a significant prior 
progression of CAC is associated with active, ongoing osteogenesis in the vessel wall. Progression of 
CAC has been reported numerous times to be associated with adverse outcomes [14–16]; hence, it 
appears legitimate to wonder if the unfavourable outcome is related to ongoing wall damage. The 
prevalence of NaF uptake was high for the type of patients we studied; these were patients in stable 
clinical conditions, on a stable medical regimen and under good metabolic control. It may appear 
contradictory that NaF uptake was seen more frequently in patients without than with prior CAC 
increase, and that no clinical or laboratory variable was associated with NaF uptake. However, a few 
considerations may clarify some of these apparent paradoxes. First, a lack of power or unknown 
confounders may have determined the outcome of the statistical analyses, although other 
explanations may also apply. Only a minority of patients was receiving statins and this may have 
favored the development of new atherosclerosis foci actively accruing microcalcifications. Although 
none of the markers of HIV infection and risk factors for atherosclerosis were associated with NaF 
uptake, this is not entirely surprising. In fact, it has been reported numerous times in the general 
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3. Discussion
Our findings are novel, as NaF imaging has never been attempted before in HIV+ patients.
Calcification is a process inherent in atherosclerotic plaque formation and it proceeds through active
mechanisms resembling bone formation; as NaF accumulates in areas of microcalcification, it is
considered an optimal tracer to detect plaque growth. We described a NaF uptake prevalence of 50%
in six arterial territories of ambulatory, stable patients infected with HIV. There was no correlation
between prior CAC progression and active vascular osteogenesis at a later time point. Several areas
of NaF uptake at the time of PET imaging did not correspond with macroscopic areas of calcification
on CT, and NaF uptake was not associated with any clinical or demographic characteristic of the
patients enrolled.
Our main intention in designing this study was to investigate whether a significant prior
progression of CAC is associated with active, ongoing osteogenesis in the vessel wall. Progression
of CAC has been reported numerous times to be associated with adverse outcomes [14–16]; hence,
it appears legitimate to wonder if the unfavourable outcome is related to ongoing wall damage.
The prevalence of NaF uptake was high for the type of patients we studied; these were patients in
stable clinical conditions, on a stable medical regimen and under good metabolic control. It may
appear contradictory that NaF uptake was seen more frequently in patients without than with prior
CAC increase, and that no clinical or laboratory variable was associated with NaF uptake. However, a
few considerations may clarify some of these apparent paradoxes. First, a lack of power or unknown
confounders may have determined the outcome of the statistical analyses, although other explanations
may also apply. Only a minority of patients was receiving statins and this may have favored the
development of new atherosclerosis foci actively accruing microcalcifications. Although none of the
markers of HIV infection and risk factors for atherosclerosis were associated with NaF uptake, this
is not entirely surprising. In fact, it has been reported numerous times in the general population,
where CAC imaging has been implemented to identify asymptomatic atherosclerosis and assess risk
of events [17,18], that as many as 50% of the patients with risk factors have no CAC, and as many as
30% of the subjects without risk factors have CAC [19]. In HIV+ positive patients, a similar concept is
reflected in the lack of a strong association between risk factors, risk scoring algorithms and presence
of subclinical atherosclerosis or occurrence of events [20]. Even adding HIV-specific factors to risk
algorithms does not increase the ability to predict risk significantly [21]. What other factors can then
induce development of atherosclerosis in these patients? And how can we better predict the occurrence
of events? HIV is a state of chronic low-grade inflammation, and immune activation as much as
immune suppression [22]. The pathological processes occurring at the level of the vessel wall may
be beyond prediction and detection based on laboratory parameters and clinical characteristics alone.
Hence, imaging may provide a means to fill the gap between clinical evidence and actual risk. In the
general population, Marnane et al. [23] showed that high 18F-fluoro-deoxy-glucose (FDG) uptake
in the carotid arteries predicted stroke recurrence. Similarly, Figeroa et al. [24], in a retrospective
analysis of oncological patients submitted to FDG imaging, showed that the ascending aorta TBR was
highly predictive of CV events at the end of a median follow-up of 4.2 years. Lee et al. [10] showed
that NaF localizes in plaques with vulnerable features on computed tomography angiography and
predicts the occurrence of acute coronary events and revascularization after two years of follow up.
In HIV+ patients, studies are slowly accumulating to demonstrate that imaging may help improve
risk prediction. For instance, Tawakol et al. [25] proved that arterial inflammation assessed with FDG
imaging is associated with high-risk plaques on CT angiography, while Raggi et al. [26] showed that
CAC and epicardial adipose tissue, a source of inflammatory chemokines, are predictive of events
in HIV+ patients. Imaging may also help detect unexpected trends in vascular health in HIV. For
example, using FDG Zanni et al. [27] showed complete disappearance of systemic inflammation
from lymphnodes and soft tissues in HIV+ patients treated with ART, but a simultaneous increase in
vascular inflammation. This was attributed to the smoldering, low-grade inflammation and immune
activation typical of patients receiving ART. In this light, the predominant uptake of NaF in arterial
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segments without macroscopic calcifications suggests that de-novo lesions are continuously being
formed on the basis of ongoing smoldering inflammation. On the other hand, the lack of correlation
between prior CAC progression and current NaF uptake may be due to the fact that older plaques have
become quiescent. Of interest, in our study, the LDL cholesterol level was significantly lower among
HIV+ patients with progression of CAC than in those without. This may be consistent with prior
observations that aggressive LDL cholesterol lowering is associated with significant CAC progression
over time, likely representing a healing phenomenon of the plaque [28]. Only two prior publications
have reported a prospective follow-up of arterial lesions imaged with a combination of NaF and CAC
imaging. Ishiwata et al. [29] imaged 34 oncological and orthopedic patients at baseline and 1 year
interval, and measured NaF uptake and CT calcium scores in the aorta and iliac arteries. Of 182
calcified sites, 96 showed NaF uptake. There was a very tenuous correlation between baseline mean
NaF uptake and change in calcification over time. However, there was a significant correlation between
maximum NaF uptake at baseline and progression of calcification at follow-up. In the experience
reported by Li et al., [30] NaF and FDG uptake and CT calcium imaging in eight arterial districts were
performed at baseline and after one year in 11 patients affected by multiple myeloma. The highest
NaF at baseline was localized on the least calcified or non-calcified arterial territories, and these were
the ones that showed most often an avid accumulation of NaF and FDG during follow-up. In contrast,
NaF accumulated less often and less intensely both at baseline and during follow-up in areas of intense
calcification. These observations once again support the view that densely calcified arterial lesions
may be quiescent and mostly healed areas of atherosclerosis.
Our study had some limitations. The sample size was relatively small and was composed
predominantly of men. The assessment of CAC progression was done prior to performing NaF
imaging and this did not allow us to assess change in a prospective manner. These are very preliminary
observations and no outcome data are available to validate the prognostic utility of NaF in the HIV+
population. There is currently no known threshold for NaF uptake that defines high vs low risk;
therefore, we used a threshold similar to that reported in prior publications [11,31] but we have no
way to know at the current state of knowledge if that threshold was too low or too high.
4. Materials and Methods
The study was approved by the Health Research Ethics Board at the University of Alberta
(Pro00058107; July 17, 2015) and the Comitato Etico Provinciale of the University of Modena and
Reggio Emilia (Protocol N. 1471, April 20, 2016). All patients signed an informed consent to participate
in the study that was conducted according to the Declaration of Helsinki for research in human
subjects (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-
medical-research-involving-human-subjects/).
4.1. Patients Selection
We enrolled 50 consecutive HIV+ patients from the Modena HIV Metabolic Clinic (MHMC),
treated for at least 6 months with stable doses of anti-retroviral therapeutic (ART) agents prior to
enrolment. MHMC is a multidisciplinary center for the diagnosis and treatment of non-infectious
co-morbidities in HIV-infected patients. Patients are assessed for lipodystrophy, diabetes mellitus,
systemic hypertension, risk and history of cardiovascular disease (CVD), osteoporosis, kidney failure,
liver and lung diseases through a comprehensive clinical evaluation and a select number of diagnostic
tests, including dual energy X-ray absorptiometry (DEXA), chest and abdominal CT scans and
laboratory tests. The thoracic and abdominal CT scans are performed to assess and quantify coronary
artery calcium (CAC), lung parenchyma abnormalities, visceral adipose tissue and liver steatosis.
To be included in the present study, patients had to have previously undergone 2 CT scans a
minimum of one year apart to assess CAC progression. All patients were ambulatory and were
receiving optimal medical therapy with stable doses (at least six months without changes) of ART, oral
or injectable hypoglycemic agents, lipid lowering and blood pressure lowering drugs. Information
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on medical history, risk factors for atherosclerotic heart disease, and medications was collected via
questionnaire and further clarified by review of the patients’ medical records.
Laboratory test results obtained within 90 days of PET/CT imaging were collected from the
electronic health records of the patients enrolled. The estimated glomerular filtration rate (eGFR) was
calculated using the CKD-Epi equation [32]. The 10-year risk of cardiovascular events was calculated
using the Pooled Equations formula according to the 2013 American College of Cardiology and
American Heart Association guidelines [33].
4.2. HIV Related History and Immuno-Virological Parameters
We recorded the plasma HIV-1 RNA levels, cumulative exposure to integrase strand transfer
inhibitors (INSTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), nucleoside reverse
transcriptase inhibitors (NRTI) and protease inhibitors (PI). An undetectable serum HIV viral load was
defined as < 40 copies/mL. Previous AIDS diagnosis was defined according to the Centers for Disease
Control group “C” category. Immunological parameters of HIV infection were T-helper lymphocyte
(CD4+) nadir, and current CD4+ and CD8+ count, as well the CD4+/CD8+ ratio.
4.3. Imaging Acquisition and Interpretation
4.3.1. Computer Tomography for Coronary Artery Calcium
All patients underwent at least two consecutive gated CT scans of the chest at a minimal interval
of 1 year and up to 2 years apart to measure changes in CAC. CT imaging was done with a Volume CT
64-slice CT scanner (GE Medical Systems, Milwaukee, WI), and was performed during a 20–30 sec
breath hold with the following CT settings: 320 mAs and 140 Kv. Image acquisition was prospectively
triggered at 80% of the R-R interval on the surface electrocardiogram and started at the level of the
bronchial carina and extended to the diaphragm in sections 2.5 mm thick. To reconstruct the raw
image data, we used a section thickness of 3.0 mm, a field of view of 20 cm2, and a matrix of 512 ×
512, yielding a nominal pixel size of 0.39 mm2 and a voxel of 0.4 mm3. The CAC score was assessed
using the “Smart Score” software (GE Medical Systems, Milwaukee, WI) on an off-line workstation.
The CAC score was calculated according to the Agatston method, as previously described [34]. CAC
progression was defined as a baseline CAC score = 0 followed by a CAC score >30, or a baseline CAC
score >30 with a yearly progression >15%. These thresholds were derived from previous studies of
CAC score reproducibility [35], and studies addressing the threshold of CAC score change associated
with an adverse outcome [14,15].
4.3.2. Positron Emission Tomography with 18F-Sodium-Fluoride
Patients received an injection of 370 MBq (10 mCi) of NaF and relaxed for 1 h before imaging.
All examinations were performed on a PET/CT system (General Electric Discovery STE, Boston, MA,
USA) with PET images obtained in 2 bed positions over the heart and aortic arch and cranial arteries
(ECG-gated list-mode PET acquisition). A 16-slice multi-detector CT scanner was used to acquire
matching data during quiet breathing (0.5 secs per rotation, 100 mAs tube current, 120 kVp tube
voltage). CT data were reconstructed in 3 mm thick slices with no overlap. PET data were obtained in
3D mode and reconstructed with iterative reconstruction (RAMLA), in 3.75 mm isotropic voxels using
CT-based attenuation correction. The global estimated radiation dose absorbed by each patient was
between 4–6 mSv. The PET/CT and the last gated chest CT scan in the sequence of CAC scoring were
performed within 1 month of each other.
4.3.3. Image Analysis
All images were reviewed on an Xeleris workstation (GE Healthcare). The PET images were scaled
with an upper standard uptake value (SUV) threshold of 2.0 and lower threshold of 0.0 for review. The
PET images, CT images, and fused PET/CT images were reviewed synchronously in multiple planes.
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The following six arterial territories were independently evaluated: aortic arch, innominate carotid
artery, right and left internal carotid arteries, left (anterior descending and circumflex combined) and
right coronary artery. The SUV max was measured in the most NaF avid focus for each artery. For
comparative blood pool measurements, we measured the SUV mean and SUV max of the superior
vena cava and left ventricle (LV) blood pool. A 2-cm diameter region of interest was placed within
the superior vena cava and the LV, avoiding myocardium, cardiac valves, and papillary muscles. The
superior vena cava blood pool SUV was used to measure the target-to-background ratio (TBR) for the
carotid arteries and aortic arch, while the LV SUV was used to calculate the coronary arteries TBR, as
SUV max (coronary)/SUV mean (LV blood pool). As suggested in prior reports, a TBR of ≥ 1.6 was
considered abnormal [29]. To limit the reproducibility error, we used only one reader for each of the
imaging studies: NP interpreted all PET studies and GL all CAC scores; each one of these experienced
readers used a semi-automatic software and the reproducibility was over 95%.
4.4. Statistical Analysis
The patients were divided in two groups depending on progression or non-progression of CAC
scores between sequential CT scans. Descriptive analyses of demographic, clinical and imaging
characteristics were performed based on CAC progression. As discussed, a TBR ≥ 1.6 was chosen to
define high NaF uptake. Means (SD) of continuous, normally distributed variables were compared
using the t-test. Medians of non-normally distributed continuous variables were compared using
the Mann-Whitney test. Percentages of categorical variables were compared using the X2 test.
Multivariable logistic regression was used to assess predictors of TBR > 1.6 using the following
variables: age, sex, LDL-c, hemoglobin A1c, total Agatston score, eGFR, use of statins, duration of
treatment with anti-retroviral medications, diabetes mellitus, and previous history of cardiovascular
disease. The Fisher exact test and the Spearman correlation coefficient were used for statistical
correlation of tracer uptake with progression and non-progression of CAC. Statistical significance was
set at p < 0.05.
5. Conclusions
In summary, in 50 clinically stable and ambulatory HIV+ patients, we did not find a correlation
between prior CAC progression and current NaF activity in several arterial beds. However, we
detected a high (50%) prevalence of arterial NaF uptake. This is a remarkably higher prevalence than
recently reported in another subset of patients at high-risk of cardiovascular disease in the general
population. In fact, only 15% of ambulatory and stable patients with diabetes mellitus had evidence of
high NaF uptake in the coronary arteries in that study [36]. This information suggests that patients
living with HIV are prone to development of atherosclerosis, even when apparently clinically stable
and metabolically well managed. The prognostic significance of these preliminary data will need to be
confirmed in larger prospective studies.
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